Lost Money on Sarepta Therapeutics, Inc.(SRPT)? Join Class Action Suit Seeking Recovery

Core Viewpoint - A class action securities lawsuit has been filed against Sarepta Therapeutics, Inc. due to alleged securities fraud affecting investors between June 22, 2023, and June 24, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that Sarepta made false statements regarding the safety of its gene therapy ELEVIDYS for Duchenne, which posed significant risks to patients [2] - It is alleged that the trial protocols for ELEVIDYS failed to identify severe side effects, leading to potential halting of recruitment and dosing in trials, increased regulatory scrutiny, and risks to therapy approvals [2] - The defendants are accused of materially misleading investors and lacking a reasonable basis for their positive statements about ELEVIDYS [2] Group 2: Next Steps for Investors - Investors who suffered losses in Sarepta during the specified timeframe have until August 25, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4] - The firm has over 70 employees and extensive expertise in complex securities litigation [4]